Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Patrick C. O'Brien net worth and biography

Patrick O'Brien Biography and Net Worth

General Counsel of Arrowhead Pharmaceuticals

Patrick C. O’Brien, General Counsel, joined the Company in December 2014. Mr. O’Brien has practiced in the healthcare legal field for over 20 years. Before joining the Company, from 2012 to 2014, Mr. O’Brien was with Shire, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 – 2010, Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 – 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.

What is Patrick C. O'Brien's net worth?: The estimated net worth of Patrick C. O'Brien is at least $7.85 million as of January 3rd, 2024. Mr. O'Brien owns 403,826 shares of Arrowhead Pharmaceuticals stock worth more than $7,854,416 as of December 21st. This net worth approximation does not reflect any other investments that Mr. O'Brien may own. Learn More about Patrick C. O'Brien's net worth.
How do I contact Patrick C. O'Brien?: The corporate mailing address for Mr. O'Brien and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Patrick C. O'Brien's contact information.
Has Patrick C. O'Brien been buying or selling shares of Arrowhead Pharmaceuticals?: Patrick C. O'Brien has not been actively trading shares of Arrowhead Pharmaceuticals within the last three months. Most recently, Patrick O'brien sold 22,841 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $35.27, for a transaction totalling $805,602.07. Following the completion of the sale, the chief operating officer now directly owns 464,385 shares of the company's stock, valued at $16,378,858.95. Learn More on Patrick C. O'Brien's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 246,092 shares worth more than $7,898,458.13. The most recent insider tranaction occured on December, 18th when CEO Christopher Richard Anzalone sold 26,712 shares worth more than $567,362.88. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 12/18/2024.

Patrick C. O'Brien Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2024	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	Sell	8,749	$32.28	$282,417.72	403,826
1/5/2023	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	Sell	17,500	$38.33	$670,775.00	363,375
1/5/2022	Sell	32,500	$61.72	$2,005,900.00
2/8/2021	Sell	90,000	$88.46	$7,961,400.00	383,375
1/6/2021	Sell	25,000	$72.41	$1,810,250.00	317,233
1/6/2020	Sell	14,625	$60.12	$879,255.00	267,406
5/28/2019	Sell	30,000	$24.88	$746,400.00	203,000
1/18/2019	Sell	72,000	$14.43	$1,038,960.00	233,000

Patrick C. O'Brien Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $19.45

$19.18

$20.21

50 Day Range

MA: $21.23

$18.32

$26.34

2 Week Range

Now: $19.45

$17.05

$39.83

Volume

4,010,988 shs

Average Volume

1,283,558 shs

Market Capitalization

$2.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.